Bladder Cancer Awareness Month 2025: Ferring partners with the community to strengthen its commitment to improve patient outcomes
The forgotten cancer: understanding the unmet need
Bladder cancer. These two words deliver a devastating impact. Every year, over 610,000 people are diagnosed with bladder cancer,1 and 1.9 million people find themselves living with the condition globally.1 Bladder cancer remains an underdiagnosed disease. Many people don’t recognise that blood in the urine requires immediate medical attention, and symptoms such as painful urination or irregular urination are frequently mistaken for other conditions, leading to delayed diagnoses and poorer outcomes.
In addition, for people with high-risk non-muscle invasive bladder cancer who don’t respond to standard Bacillus Calmette Guérin (BCG) treatment, options have traditionally been limited. Up to 50% of patients receiving initial BCG treatment experience disease recurrence and / or progression within one year.2 Cystectomy – removal of the bladder – is the most definitive treatment but is associated with significant risk of complications and increased mortality.
Ferring’s commitment to advancing bladder cancer care
As Bladder Cancer Awareness Month begins, Ferring reaffirms its commitment to patients affected by non-muscle invasive bladder cancer. Adstiladrin® (nadofaragene firadenovec-vncg) is a non-replicating adenovirus vector-based gene therapy, approved by the U.S. FDA, for the treatment of adult patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumours.
Ferring continues to invest in clinical trials and gather real-world evidence to further understand how its treatments can benefit patients. This ongoing research, alongside investment in state-of-the-art manufacturing facilities, reinforces Ferring’s long-term commitment to bladder cancer patients globally, aiming to improve patient’s quality of life and give them more choices in how they manage their condition.
Ferring and bladder cancer awareness month
This May, Ferring is proud to partner with the World Bladder Cancer Patient Coalition and support its 2025 campaign, which focuses on “Challenging Uncertainty”: “Feeling unsure? Get checked.”
- You can participate in this important month of awareness through several initiatives:
- Follow and share content using the hashtags #BladderCancerAware and #FeelingUnsureGetChecked
- Visit the WBCPC website to learn about their “Unsure Icon,” which helps spark conversations about bladder cancer symptoms and try the interactive online game “Spot the Drop!” connecting the discovery of blood in urine to taking action
- Join the global conversation on social media about the importance of early detection and patient choice in treatment decisions
Supporting patient care
Bladder Cancer Awareness Month provides an opportunity to highlight the importance of early detection and treatment options. Ferring supports efforts to raise awareness about bladder cancer symptoms and treatment choices, working alongside healthcare professionals and patient advocacy groups.
By contributing to the broader conversation about bladder cancer care, Ferring aims to help ensure that patients have access to information about their condition and the treatment options available to them.
For more information about Ferring’s activities in uro-oncology, visit Bladder cancer – Ferring Global.
References
- World Bladder Cancer Patient Coalition. Bladder Cancer Awareness Month. Available at: Bladder Cancer Awareness Month – May 2025. Last accessed April 2025.
- Deng S, et al. Global research trends in non-muscle invasive bladder cancer: Bibliometric and visualized analysis. Front Oncol. 2022; 12:1044830.
